ArticleScientific reports2025
Clinical features of hearing loss and genotype-phenotype correlations in Alport syndrome caused by COL4A4 or COL4A5 variants.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bibliometric analysis of Alport syndrome: genetic foundations, clinical implications, and the transition to precision medicine.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Alport syndrome (AS) is a genetic disorder characterized by progressive nephritis, hearing loss, and visual impairment. Quantitative analyses of hearing in AS are rare. We conducted a retrospective chart review of clinical features and longitudinal follow-up of patients with AS, including multiple evaluations of pure-tone audiograms in each individual and examination of the relationships between hearing loss and genetic variants. Twelve AS cases from eight Japanese families were studied: one family had an autosomal dominant COL4A4 variant and seven carried X-linked variants in COL4A5; all cases presented with moderate hearing loss. Progression of hearing loss was 0.25, 0.29, 0.57, and 2.60 dB HL/year at 500, 1000, 4000, and 8000 Hz, respectively. During follow-up (1-10 years), all families exhibited mid-frequency hearing loss. Hearing loss onset occurred later than renal symptoms in all patients with COL4A5 variants, and the COL4A4 variant did not cause renal symptoms. Hearing loss severity and age of onset appeared to vary depending on the characteristics of the genetic variants, indicating genotype-phenotype correlations; however, hearing decline was predominantly at high frequencies, regardless of genetic variation. These findings provide valuable insights into genotype-phenotype correlations in AS, particularly regarding hearing loss progression and characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.